Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
Neural Regulation01:37

Neural Regulation

43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.

The Lancet. Neurology·2026
Same author

Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.

JAMA neurology·2026
Same author

Closing the Gate Before the Horse is out of the Barn: A Model to Effectively Predict the First Fall in Patients with Parkinson's Disease.

Movement disorders clinical practice·2026
Same author

Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center.

Parkinsonism & related disorders·2026
Same author

Data-driven neurobiological subtyping of Parkinson's disease using diffusion MRI-derived isotropic diffusion.

Neuroradiology·2026
Same author

Persistent Head Tremor Improvement in Essential Tremor Patients after Bilateral Ventral Intermediate Nucleus DBS.

Movement disorders clinical practice·2025

Related Experiment Videos

2015 Update on Parkinson disease.

Hubert H Fernandez1,2

  • 1Section Head, Center for Neuro-Restoration, Cleveland Clinic, Cleveland, OH, USA.

Cleveland Clinic Journal of Medicine
|September 15, 2015
PubMed
Summary

Parkinson disease diagnosis relies on clinical signs, with levodopa remaining the primary treatment. Ongoing research into Parkinson disease pathogenesis is paving the way for novel diagnostic methods and therapies.

Area of Science:

  • Neuroscience
  • Neurology
  • Medical Diagnostics

Background:

  • Parkinson disease diagnosis is currently based on clinical அறிகுறிகள்.
  • Levodopa is the most effective treatment for Parkinson disease.

Purpose of the Study:

  • To explore advancements in Parkinson disease diagnostics and treatments.
  • To highlight the impact of improved disease understanding on clinical practice.

Main Methods:

  • Review of current diagnostic criteria for Parkinson disease.
  • Analysis of the role of levodopa in Parkinson disease management.
  • Exploration of emerging research in Parkinson disease biomarkers and therapeutics.

Main Results:

  • Clinical diagnosis remains the standard for Parkinson disease.

Related Experiment Videos

  • Levodopa continues to be the cornerstone of symptomatic treatment.
  • New diagnostic tools and therapeutic strategies are under development.

    • Conclusions:

    • Despite challenges, the understanding of Parkinson disease is advancing.
    • These advancements promise improved diagnostic accuracy and more effective treatments for Parkinson disease patients.